AVEO Pharmaceuticals, Inc. (AVEO) was a big mover last session, as its shares rose over 7% on the day. The upside was driven by news of a potential approval of the company’s drug tivozanib in Europe. This also led to far more shares changing hands than in a normal session. Yesterday’s rally continues the recent uptrend for the company, as the stock is now up almost 59% in the past one-month time frame.
Over the last 30 days, the company did not witness any estimate revision and the Zacks Consensus Estimate also remained unchanged. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
AVEO Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
A better-ranked biomedical stock is Affymetrix Inc. (AFFX) with a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment